Dr. Hamilton on the DESTINY-Breast01 Trial in HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Wednesday, Feb 05, 2020



Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the phase II DESTINY-Breast01 trial in advanced HER2-positive breast cancer.

In the trial, patients with heavily pretreated HER2-positive breast cancer received trastuzumab deruxtecan-nxki (Enhertu; DS-8201). Patients had a median of 6 prior lines of therapy in the metastatic setting. After a median follow-up of 11.1 months, the median progression-free survival (PFS) with the agent was 16.4 months in all comers, and 18.1 months in patients with brain metastases.

In addition, trastuzumab deruxtecan-nxki has shown signals of activity in patients with HER2-low disease, says Hamilton. The drug is currently under investigation in the phase III DESTINY-Breast04 trial, where patients will be randomized to receive either trastuzumab deruxtecan or investigator’s choice. If the trial is positive, it may redefine the meaning of HER2-positivity and provide treatment for patients who would have otherwise been denied HER2-targeted therapy, concludes Hamilton.
SELECTED
LANGUAGE


Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the phase II DESTINY-Breast01 trial in advanced HER2-positive breast cancer.

In the trial, patients with heavily pretreated HER2-positive breast cancer received trastuzumab deruxtecan-nxki (Enhertu; DS-8201). Patients had a median of 6 prior lines of therapy in the metastatic setting. After a median follow-up of 11.1 months, the median progression-free survival (PFS) with the agent was 16.4 months in all comers, and 18.1 months in patients with brain metastases.

In addition, trastuzumab deruxtecan-nxki has shown signals of activity in patients with HER2-low disease, says Hamilton. The drug is currently under investigation in the phase III DESTINY-Breast04 trial, where patients will be randomized to receive either trastuzumab deruxtecan or investigator’s choice. If the trial is positive, it may redefine the meaning of HER2-positivity and provide treatment for patients who would have otherwise been denied HER2-targeted therapy, concludes Hamilton.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x